title: Preterm infant formula supplementation with alpha linolenic acid and docosahexaenoic acid.
abstract: OBJECTIVE
  To investigate if supplementation of preterm infant formula with a high docosahexaenoic acid/eicosapentaenoic acid (DHA/EPA) ratio together with alpha-linolenic acid (ALA) was able to maintain plasma and red blood cell DHA levels similar to that obtained with breast milk feeding without altering n-6 fatty acid status.
  
  
  METHODS
  Preterm infants of mothers who elected not to breast feed (n=13) were assigned to ALA- and DHA-enriched formula (DHA group: DHA/EPA=5/l). Infants fed breast milk (n=25) constituted a reference group (BM group). Anthropometric and fatty acid parameters (plasma phospholipids, cholesterol esters, triglycerides and red blood cell phosphatidylethanolamine, PL, CE, TG, RBC-PE, respectively) were obtained after 2 days (D2) and 15 days (D15) of enteral feeding and at the 37th week (W37) of post-conception age and 1 month later (W37+30) in the DHA group. Mean DHA intake ranged between 16.5+/-1.6 and 17.9+/-2.9 mg/kg/day between D2 and W37+30.
  
  
  RESULTS
  At W37, infant weights, heights, and head circumferences were similar in DHA and BM groups. PL DHA was maintained in the DHA group at the same level as in the BM group and the same for DHA in PE at W37. In RBC-PE and at W37, AA status was the same in both groups. In PL, AA levels remained very stable throughout the study; however, in the DHA group AA levels in PL remained in the range observed with standard formulas.
  
  
  CONCLUSIONS
  The combined 18:3 n-3 and DHA supplementation of infant formula with DHA/EPA ratio 5/l is compatible with growth and n-3 fatty acid metabolism similar to that of preterm infants fed human milk.
authors.affiliation: Laboratoire de Biochimie A, EA Nutrition Humaine et Athérogenèse, UMI, Institut de Biologie, Boulevard Henri IV, 34060 Montpellier, France.
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez
authors.forename: D
authors.initials: D
authors.lastname: Raederstorff
authors.forename: P
authors.initials: P
authors.lastname: Sarda
authors.forename: C
authors.initials: C
authors.lastname: Lauret
authors.forename: F
authors.initials: F
authors.lastname: Mendy
authors.forename: B
authors.initials: B
authors.lastname: Descomps
mesh_terms: D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism*; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007225:Infant Food; D007231:Infant, Newborn; D007234:Infant, Premature; D008895:Milk, Human / Q000378:metabolism; D017962:alpha-Linolenic Acid / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D015525:Fatty Acids, Omega-3; D017962:alpha-Linolenic Acid; D004281:Docosahexaenoic Acids